Ignite Creation Date:
2025-12-24 @ 1:17 PM
Ignite Modification Date:
2025-12-29 @ 10:13 PM
Study NCT ID:
NCT06764095
Status:
RECRUITING
Last Update Posted:
2025-09-15
First Post:
2024-12-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Sponsor:
Mayo Clinic
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-01-08
Start Date Type:
ACTUAL
Primary Completion Date:
2034-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2034-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-12-27
First Submit QC Date:
None
Study First Post Date:
2025-01-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-09
Last Update Post Date:
2025-09-15
Last Update Post Date Type:
ESTIMATED